Option Care Health (OPCH) experienced a share price decline following Argenx's (ARGX, Financial) announcement of FDA approval for Vyvgart Hytrulo as a self-administered pre-filled syringe. This development is believed to have contributed to the downward pressure on OPCH shares. However, analysts at JPMorgan suggest that this news is unlikely to significantly impact Option Care's financial performance.
JPMorgan highlights that Option Care Health has previously indicated that no single medication, other than Stelara, represents more than 5% of its overall revenue. This diversification in revenue sources suggests that Vyvgart Hytrulo's approval will not materially alter the company's financial outlook.
The financial firm perceives the recent stock pullback as an advantageous entry point for investors and consequently reaffirms its Overweight rating on Option Care Health. This assessment underscores the belief in the company's robust market position and potential for future growth.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for argenx SE (ARGX, Financial) is $726.52 with a high estimate of $1,100.00 and a low estimate of $416.00. The average target implies an upside of 25.18% from the current price of $580.40. More detailed estimate data can be found on the argenx SE (ARGX) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, argenx SE's (ARGX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for argenx SE (ARGX, Financial) in one year is $1899.70, suggesting a upside of 227.31% from the current price of $580.4. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the argenx SE (ARGX) Summary page.
